• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

3-磷酸肌醇依赖的激酶 1 通过激酶依赖性而非 Akt 独立性控制乳腺癌的生长。

3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner.

机构信息

Institute for Cancer Research and Treatment, Candiolo, Italy.

出版信息

Neoplasia. 2012 Aug;14(8):719-31. doi: 10.1593/neo.12856.

DOI:10.1593/neo.12856
PMID:22952425
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3431179/
Abstract

3-phosphoinositide-dependent protein kinase 1 (PDK1) is the pivotal element of the phosphatidylinositol 3 kinase (PI3K) signaling pathway because it phosphorylates Akt/PKB through interactions with phosphatidylinositol 3,4,5 phosphate. Recent data indicate that PDK1 is overexpressed in many breast carcinomas and that alterations of PDK1 are critical in the context of oncogenic PI3K activation. However, the role of PDK1 in tumor progression is still controversial. Here, we show that PDK1 is required for anchorage-independent and xenograft growth of breast cancer cells harboring either PI3KCA or KRAS mutations. In fact, PDK1 silencing leads to increased anoikis, reduced soft agar growth, and pronounced apoptosis inside tumors. Interestingly, these phenotypes are reverted by PDK1 wild-type but not kinase-dead mutant, suggesting a relevant role of PDK1 kinase activity, even if PDK1 is not relevant for Akt activation here. Indeed, the expression of constitutively active forms of Akt in PDK1 knockdown cells is unable to rescue the anchorage-independent growth. In addition, Akt down-regulation and pharmacological inhibition do not inhibit the effects of PDK1 overexpression. In summary, these results suggest that PDK1 may contribute to breast cancer, even in the absence of PI3K oncogenic mutations and through both Akt-dependent and Akt-independent mechanisms.

摘要

3-磷酸肌醇依赖性蛋白激酶 1(PDK1)是磷脂酰肌醇 3 激酶(PI3K)信号通路的关键组成部分,因为它通过与磷脂酰肌醇 3,4,5 磷酸相互作用来磷酸化 Akt/PKB。最近的数据表明,PDK1 在许多乳腺癌中过表达,并且 PDK1 的改变在致癌性 PI3K 激活的情况下是至关重要的。然而,PDK1 在肿瘤进展中的作用仍然存在争议。在这里,我们表明 PDK1 是携带 PI3KCA 或 KRAS 突变的乳腺癌细胞锚定非依赖性和异种移植物生长所必需的。事实上,PDK1 沉默导致凋亡增加、软琼脂生长减少和肿瘤内明显凋亡。有趣的是,这些表型可以通过 PDK1 野生型而不是激酶失活突变型逆转,这表明 PDK1 激酶活性具有重要作用,即使在这里 Akt 的激活与 PDK1 无关。事实上,在 PDK1 敲低细胞中表达组成激活形式的 Akt 不能挽救锚定非依赖性生长。此外,Akt 下调和药理学抑制并不能抑制 PDK1 过表达的作用。总之,这些结果表明,PDK1 可能有助于乳腺癌的发生,即使在没有 PI3K 致癌突变的情况下,并且通过 Akt 依赖和 Akt 独立的机制。

相似文献

1
3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner.3-磷酸肌醇依赖的激酶 1 通过激酶依赖性而非 Akt 独立性控制乳腺癌的生长。
Neoplasia. 2012 Aug;14(8):719-31. doi: 10.1593/neo.12856.
2
RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.RET/PTC(在转化/甲状腺乳头状癌中重排)酪氨酸激酶使磷酸肌醇依赖性激酶1(PDK1)磷酸化并激活:一条独立于磷脂酰肌醇3激酶激活PDK1的替代途径。
Mol Endocrinol. 2003 Jul;17(7):1382-94. doi: 10.1210/me.2002-0402. Epub 2003 May 8.
3
Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells.Runx2通过mTORC2调控激活侵袭性乳腺癌细胞中的PI3K/Akt信号通路。
Breast Cancer Res. 2014 Jan 30;16(1):R16. doi: 10.1186/bcr3611.
4
IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation.IKBKE 蛋白通过磷脂酰肌醇 3-激酶/PDK1/mTORC2 和pleckstrin 同源结构域激活 Akt,以维持恶性转化。
J Biol Chem. 2011 Oct 28;286(43):37389-98. doi: 10.1074/jbc.M111.287433. Epub 2011 Sep 9.
5
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.3-磷酸肌醇依赖性激酶1增强乳腺癌中磷脂酰肌醇3-激酶途径的上游损伤。
Cancer Res. 2009 Aug 1;69(15):6299-306. doi: 10.1158/0008-5472.CAN-09-0820. Epub 2009 Jul 14.
6
Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival.H-RAS和K-RAS的激活形式对PI3K、PDK-1和AKT的膜结合以及治疗性激酶抑制剂对细胞存活的影响具有不同的调节作用。
Mol Cancer Ther. 2005 Feb;4(2):257-70.
7
Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines.对Ras、磷酸肌醇3激酶和Akt亚型的选择性抑制可提高人癌细胞系的放射敏感性。
Cancer Res. 2005 Sep 1;65(17):7902-10. doi: 10.1158/0008-5472.CAN-05-0513.
8
PKCdelta survival signaling in cells containing an activated p21Ras protein requires PDK1.在含有活化p21Ras蛋白的细胞中,蛋白激酶Cδ(PKCδ)的存活信号传导需要3-磷酸肌醇依赖性蛋白激酶-1(PDK1)。
Cell Signal. 2009 Apr;21(4):502-8. doi: 10.1016/j.cellsig.2008.12.002. Epub 2008 Dec 10.
9
Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.核内不均一核糖核蛋白 A2B1 与胰腺导管腺癌细胞中的致癌 KRAS 相互作用并调节其活性。
Gastroenterology. 2014 Oct;147(4):882-892.e8. doi: 10.1053/j.gastro.2014.06.041. Epub 2014 Jul 3.
10
Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast.哺乳动物PI3K/PTEN/Akt信号通路在酵母中的重建。
Biochem J. 2005 Sep 1;390(Pt 2):613-23. doi: 10.1042/BJ20050574.

引用本文的文献

1
Activation of the WNT4/ β-catenin/FOXO1 pathway by PDK1 promotes cervical cancer metastasis and EMT process.PDK1激活WNT4/β-连环蛋白/FOXO1信号通路可促进宫颈癌转移和上皮-间质转化过程。
J Mol Histol. 2025 Jan 9;56(1):68. doi: 10.1007/s10735-024-10342-x.
2
Estrogen regulates PDPK1 to promote cell proliferation in epithelial ovarian cancer.雌激素通过调节丙酮酸脱氢酶激酶1(PDPK1)来促进上皮性卵巢癌的细胞增殖。
Heliyon. 2024 Nov 8;10(22):e40296. doi: 10.1016/j.heliyon.2024.e40296. eCollection 2024 Nov 30.
3
3-Phosphoinositide-Dependent Kinase 1 as a Therapeutic Target for Treating Diabetes.3-磷酸肌醇依赖性激酶1作为治疗糖尿病的治疗靶点。
Curr Diabetes Rev. 2025;21(4):47-56. doi: 10.2174/0115733998278669240226061329.
4
Disruption of Autophagic Flux and Treatment with the PDPK1 Inhibitor GSK2334470 Synergistically Inhibit Renal Cell Carcinoma Pathogenesis.自噬通量的破坏与PDPK1抑制剂GSK2334470联合治疗协同抑制肾细胞癌的发生发展。
J Cancer. 2024 Jan 20;15(5):1429-1441. doi: 10.7150/jca.92521. eCollection 2024.
5
Anoikis resistance--protagonists of breast cancer cells survive and metastasize after ECM detachment.失巢凋亡抵抗——细胞外基质解离后乳腺癌细胞存活和转移的主角。
Cell Commun Signal. 2023 Aug 3;21(1):190. doi: 10.1186/s12964-023-01183-4.
6
Analysis of the epidermal growth factor receptor/phosphoinositide-dependent protein kinase-1 axis in tumor of the external auditory canal in response to epidermal growth factor stimulation.表皮生长因子受体/磷酸肌醇依赖性蛋白激酶-1轴在外耳道肿瘤中对表皮生长因子刺激的反应分析。
Laryngoscope Investig Otolaryngol. 2022 Mar 30;7(3):730-739. doi: 10.1002/lio2.785. eCollection 2022 Jun.
7
A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.全基因组筛选鉴定出 PDPK1 是增强 MEK1/2 抑制剂在NRAS 突变型黑色素瘤中的疗效的靶点。
Cancer Res. 2022 Jul 18;82(14):2625-2639. doi: 10.1158/0008-5472.CAN-21-3217.
8
The Landscape of PDK1 in Breast Cancer.乳腺癌中PDK1的概况
Cancers (Basel). 2022 Feb 5;14(3):811. doi: 10.3390/cancers14030811.
9
Phosphoinositide-Dependent Protein Kinases Regulate Cell Cycle Progression Through the SAD Kinase Cdr2 in Fission Yeast.磷脂酰肌醇依赖性蛋白激酶通过裂殖酵母中的SAD激酶Cdr2调节细胞周期进程。
Front Microbiol. 2022 Jan 10;12:807148. doi: 10.3389/fmicb.2021.807148. eCollection 2021.
10
Baicalin Inhibits EMT through PDK1/AKT Signaling in Human Nonsmall Cell Lung Cancer.黄芩苷通过PDK1/AKT信号通路抑制人非小细胞肺癌中的上皮-间质转化
J Oncol. 2021 Nov 25;2021:4391581. doi: 10.1155/2021/4391581. eCollection 2021.

本文引用的文献

1
A novel regulatory mechanism links PLCγ1 to PDK1.一种新的调控机制将 PLCγ1 与 PDK1 联系起来。
J Cell Sci. 2012 Jul 1;125(Pt 13):3153-63. doi: 10.1242/jcs.100511. Epub 2012 Mar 27.
2
PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models.PDK1 失活不能预防 PTEN 缺失型转基因小鼠模型中的肿瘤形成。
Cancer Res. 2011 Apr 15;71(8):3052-65. doi: 10.1158/0008-5472.CAN-10-2282.
3
Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.基于结构的强效和选择性 3-磷酸肌醇依赖性激酶-1(PDK1)抑制剂的设计。
J Med Chem. 2011 Mar 24;54(6):1871-95. doi: 10.1021/jm101527u. Epub 2011 Feb 22.
4
Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.针对乳腺癌中的磷酸肌醇-3(PI3)激酶途径。
Oncologist. 2011;16 Suppl 1:12-9. doi: 10.1634/theoncologist.2011-S1-12.
5
Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.在癌细胞中遗传和药理学抑制 PDK1:一种选择性别构激酶抑制剂的特征。
J Biol Chem. 2011 Feb 25;286(8):6433-48. doi: 10.1074/jbc.M110.156463. Epub 2010 Nov 30.
6
Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1.GSK2334470 是一种新型、高度特异的 PDK1 抑制剂,其特征如下。
Biochem J. 2011 Jan 15;433(2):357-69. doi: 10.1042/BJ20101732.
7
B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer.B55β 相关的 PP2A 复合物控制 PDK1 定向的 myc 信号转导并调节结直肠癌细胞对雷帕霉素的敏感性。
Cancer Cell. 2010 Nov 16;18(5):459-71. doi: 10.1016/j.ccr.2010.10.021.
8
PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer.选择正确的异构体:p110β 亚基在乳腺癌中的新兴作用。
Virchows Arch. 2010 Mar;456(3):235-43. doi: 10.1007/s00428-010-0881-0. Epub 2010 Feb 4.
9
A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.基于肌醇 1,3,4,5,6-五磷酸结构的新型 PI3K/Akt 通路抑制剂。
Br J Cancer. 2010 Jan 5;102(1):104-14. doi: 10.1038/sj.bjc.6605408.
10
The nuts and bolts of AGC protein kinases.AGC 蛋白激酶的要点。
Nat Rev Mol Cell Biol. 2010 Jan;11(1):9-22. doi: 10.1038/nrm2822.